IMMX: Immix Biopharma, Inc.
Performance
IMMX +172.06%
Watchlist
Select an item
Summary
IMMX at a glance
IMMX returned +172.06% over the past year. Its worst drop in that year was -50.24%, smaller than 23% of stocks on Redstone, and its Sharpe ratio of 1.57 beats 93% of stocks on Redstone. It pays no dividends.
Current Drawdown
-40.77%
Rolling Volatility
84.62%
Actions
Metrics
Risk Indicators
Alpha115.10%
Beta1.70x
Sharpe1.57
Sortino2.58
Omega1.29
Calmar3.42
Martin6.14
Profile
About IMMX
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $710M
- Listed
- Dec 2021
- Employees
- 21
- Headquarters
- Los Angeles, CA
- Website
- immixbio.com
Comparisons